<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122025">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01514162</url>
  </required_header>
  <id_info>
    <org_study_id>1003</org_study_id>
    <nct_id>NCT01514162</nct_id>
  </id_info>
  <brief_title>Post-Approval Study Protocol of the St. Jude Medical Trifecta Valve</brief_title>
  <official_title>Post-Approval Study Protocol of the St. Jude Medical Trifecta Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To further evaluate the long term clinical safety and effectiveness of the Trifecta valve in
      subjects who had a Trifecta valve implanted during the IDE study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint</measure>
    <time_frame>5 years</time_frame>
    <description>Report late adverse event rates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint</measure>
    <time_frame>5 years</time_frame>
    <description>To report subject NYHA functional classification status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint</measure>
    <time_frame>5 years</time_frame>
    <description>To report the hemodynamic performance of the valve, as per echocardiography</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">245</enrollment>
  <condition>Subjects Implanted With a Trifecta Valve.</condition>
  <arm_group>
    <arm_group_label>Trifecta Valve Group</arm_group_label>
    <description>Subjects implanted with a Trifecta valve.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects implanted with a Trifecta valve.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects implanted with a Trifecta valve at one of the US sites of the IDE study.

          -  Subject met eligibility criteria of IDE study

          -  Subject agrees to complete study follow-up visits

          -  Subject provides written informed consent

        Exclusion Criteria:

          -  Subject currently participating in another device or drug study

          -  Subject unable or unwilling to return for study follow-up visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital Cardiac Surgical Associates</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Heart Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Heart &amp; Lung Surgical Associates</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 9, 2015</lastchanged_date>
  <firstreceived_date>January 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trifecta Valve</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
